This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zogenix Provides Update On Zohydro(TM) ER (hydrocodone Bitartrate) Launch Readiness Plans

SAN DIEGO, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it has made significant progress in preparing for the market launch of Zohydro TM ER (hydrocodone bitartrate) extended-release capsules, approved by the U.S. Food and Drug Administration in October 2013. Zohydro ER, the first and only extended release hydrocodone without acetaminophen, is indicated for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. For patients managing chronic pain with an immediate release hydrocodone combination product, an extended release formulation without the risks associated with acetaminophen may be beneficial. Zohydro ER may also be an alternative for people living with chronic pain who have developed opioid tolerance or are experiencing side effects with other long-acting opioids.

In preparation for commercial launch, the company has completed a significant organizational expansion, increasing its employee footprint to approximately 250. Zogenix has recruited professionals with extensive experience in the pain management marketplace to contribute to a full range of commercial operations including sales and marketing, managed markets and trade team. Zogenix has also assembled an impressive medical affairs leadership team as announced in December 2013. All 150 territory representative positions have been filled and comprehensive training began February 3 rd, and will continue throughout the month. Manufacturing of Zohydro ER has also been completed and the product is ready for shipment to wholesalers. The company believes that adequate inventory is in place to meet anticipated launch demand for the product.

These preparations place Zohydro ER's commercial launch on track for early March.

About Zohydro ER


Zohydro™ ER is an opioid agonist, extended-release, oral formulation of hydrocodone bitartrate indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs